Impax reports £1.4bn inflows amid 'unprecedented' environmental awareness

AUM shoots up to £15.1bn

Anna Fedorova
clock • 2 min read

Sustainable investment specialist Impax Asset Management has enjoyed net inflows of £1.4bn during a year which has seen "unprecedented concern globally about environmental issues".

Over 12 months to 30 September, the firm has increased assets under management (AUM) by 21% to £15.1bn thanks to strong inflows into the majority of its products, including segregated mandates. The two months to the end of November saw additional net inflows of £500m, contributing to AUM rising to £15.7bn. However, the majority of the inflows were taken in by the group's listed equities products, while fixed income, smart-beta and US equities saw net outflows of £251m over the period. The group said flows into Pax World Funds, which it acquired along with Pax World Management in 20...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Specialist

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

‘Dedicated specialists’

James Baxter-Derrington
clock 06 April 2023 • 4 min read
European private equity yet to spend €270bn worth of capital

European private equity yet to spend €270bn worth of capital

Deployment of capital expected

Kathleen Gallagher
clock 04 January 2023 • 1 min read
Early-stage biopharma: An opportunity for strategic investment

Early-stage biopharma: An opportunity for strategic investment

Disproportionately smaller investment

Ali H. Munawar
clock 10 August 2022 • 4 min read
Trustpilot